Advanced in Peripheral Neuropathy

Yu-min Yeh

138 Sheng Li Road, 
Tainan, TNQ, TW 
Advanced in Peripheral Neuropathy
138 Sheng Li Road, 
Tainan, TNQ, TW 
OverviewLocationsClinical Research

Overview

Yu-min Yeh practices in Tainan, Taiwan. Mr. Yeh is rated as an Advanced expert by MediFind in the treatment of Peripheral Neuropathy. His top areas of expertise are Colorectal Cancer, Peripheral Neuropathy, Metastatic Brain Tumor, and Breast Cancer in Men.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Peripheral Neuropathy.

Gender
Male

Locations

138 Sheng Li Road, Tainan, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-center Phase II Study of AUY922 in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed After One Line of Systemic Therapy
A Multi-center Phase II Study of AUY922 in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed After One Line of Systemic Therapy
Enrollment Status: Completed
Publish Date: July 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase IB/II, Open Label, Multicenter Study of Selumetinib Administered Orally in Combination With Gefitinib in Patients With EGFR-mutated Non-small Cell Lung Cancer Who Have Developed Acquired Resistance of EGFR Inhibitor Treatment
A Phase IB/II, Open Label, Multicenter Study of Selumetinib Administered Orally in Combination With Gefitinib in Patients With EGFR-mutated Non-small Cell Lung Cancer Who Have Developed Acquired Resistance of EGFR Inhibitor Treatment
Enrollment Status: Completed
Publish Date: July 10, 2018
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

45 Total Publications

Cathepsin S regulates antitumor immunity through autophagic degradation of PD-L1 in colorectal cancer cells.
Cathepsin S regulates antitumor immunity through autophagic degradation of PD-L1 in colorectal cancer cells.
Journal: Cancer immunology, immunotherapy : CII
Published: June 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yeh's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile